Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData ...

Readers were also hungry for news about Ozempic, Wegovy, Zepbound and new-generation weight-loss drugs. 1. Ex-Aetna CEO calls for end to employer-based health coverage Mark Bertolini, ex-CEO of ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

“From the start, Zepbound emerged as the primary new competitor of Wegovy, and it seems that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population ...

Mizuho healthcare expert Jared Holz wrote in a note that it's doubtful "patients are seeking to lose more weight than what drugs like Zepbound and Wegovy are providing." Zepbound, Eli Lilly's (LLY ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Mizuho healthcare expert Jared Holz wrote in a note that it's doubtful "patients are seeking to lose more weight than what drugs like Zepbound and Wegovy are providing." Zepbound, Eli Lilly's (LLY) ...